BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

CeraPedics, Inc. Receives CE Mark for i-FACTOR Flex Bone Graft


6/30/2010 6:54:56 AM

WESTMINSTER, Colo.--(BUSINESS WIRE)--Cerapedics, Inc., a medical device company focused on developing and commercializing novel osteobiologic products, announced today that it received the CE Mark for its i-FACTOR™ Flex bone graft product line. i-FACTOR Flex is the company’s second product in the i-FACTOR product platform based on its proprietary small peptide attachment factor technology.

i-FACTOR bone graft is the only biologic bone graft that combines a unique anorganic bone mineral (ABM) and small peptide (P-15™) to act as an attachment factor for specific integrins on osteogenic cells. This novel mechanism of action enhances the body’s natural bone healing process resulting in safe, predictable bone formation at a lower cost than growth factors. ABM/P-15 has been in human clinical use for more than thirteen years in an estimated 500,000 patients worldwide.

“We are pleased to now offer another dimension of the i-FACTOR bone graft product portfolio to our customers in Europe and Asia Pacific,” said Steve McAdoo, director of marketing at Cerapedics. “i-FACTOR Flex is a freeze-dried form of i-FACTOR Putty, providing complementary handling characteristics surgeons may require in addressing spine, trauma and orthopedic indications.”

Cerapedics’ flagship product i-FACTOR Putty bone graft received CE Mark in late 2008. It has been utilized clinically in more than 2,000 spine and trauma surgeries worldwide. i-FACTOR bone graft is currently being evaluated in the United States (FDA) as part of an Investigational Device Exemption (IDE) Clinical Study in spine.

Paul Mraz, CEO, said, “We continue to be highly encouraged with the long-term clinical results from the initial market release of i-FACTOR Putty that began in Europe in 2008. i-FACTOR’s peptide enhanced cellular attachment factor, a unique mechanism of action among bone grafts, is now available in more than 20 countries worldwide and growing. Cerapedics continues to be well-positioned in the increasingly sophisticated osteobiologics marketplace.”

About Cerapedics, Inc. Cerapedics is a privately-held medical device company focused on developing and commercializing novel osteobiologic products based on its proprietary small peptide attachment factor technology platform.

i-FACTOR™ is the only biologic bone graft that utilizes a small peptide (P-15™) as an attachment factor to stimulate the natural bone healing process resulting in safe, predictable bone formation at a fraction of the cost of growth factors.

Cerapedics – Enhancing the Science of Bone Repair™. More information can be found at www.cerapedics.com.

Contact:

Cerapedics, Inc. Kathryn Yankowsky, 303-974-6275 Marketing Manager info@cerapedics.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->